Walleye Trading
ELVN icon

Walleye Trading’s Enliven Therapeutics ELVN Stock Holding History

Walleye Trading’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,808
Closed -$176K – 5461
2021
Q3 		$176K Buy
+10,808
New +$225K ﹤0.01% 3994
2021
Q2 		– Sell
-3,945
Closed -$133K – 5245
2021
Q1 		$133K Buy
+3,945
New +$200K ﹤0.01% 3941

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Walleye Trading's ELVN Position: Q4 2021 in Review

Walleye Trading sold out of Enliven Therapeutics (ELVN) in Q4 2021, closing a stake of 10,808 shares — an estimated $176K sold.

Walleye Trading first reported a position in ELVN in Q1 2021 and held it in 2 quarters. The position peaked at $176K in Q3 2021. 35 funds tracked by Wall St. Rank hold ELVN as of Q4 2021.

  • Walleye Trading reported no remaining Enliven Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Walleye Trading sold 10,808 Enliven Therapeutics shares in Q4 2021, an estimated $176K.
  • Walleye Trading first reported a position in Enliven Therapeutics in Q1 2021 and held it in 2 quarters.
  • Walleye Trading's Enliven Therapeutics position peaked at $176K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.